Investor Overview


Corporate Profile

Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within. Tocagen is currently studying its lead product candidate, Toca 511 & Toca FC, in a Phase 3 clinical trial for the treatment of patients with recurrent high grade glioma (HGG), a type of brain cancer with limited treatment options. Toca 511 & Toca FC has been granted Breakthrough Therapy Designation for the treatment of patients with recurrent HGG by the FDA, and PRIME (PRIority MEdicines) designation by the European Medicines Agency.
Webcast ImageWebcast
Chardan Capital Markets 2nd Annual Genetic Medicines Conference (Replay)
10/09/18 at 3:45 p.m. ET
Chardan Capital Markets 2nd Annual Genetic Medicines Conference
Tuesday, October 9, 2018 3:45 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
NASDAQ GS TOCA (Common Stock)
$12.58 - 0.23
Stock chart for: TOCA.O.  Currently trading at $12.58 with a 52 week high of $15.80 and a 52 week low of $7.52.
10/15/18 9:42 a.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News

View All  

Tocagen Provides Update on European Regulatory Path for Toca 511 & Toca FC

10/02/18

Read More

Tocagen Presents Preliminary Data from Toca 6 Trial Supportive of Immune Activation in Patients with Advanced Solid Tumors at CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

09/30/18

Read More

Tocagen to Participate in Four Investor Conferences in October

09/27/18

Read More